DEF: Waters Corporation Annual Meeting Proxy Statement Highlights

Waters Corporation's 2026 proxy statement details strong 2025 financial performance, the acquisition of BD's Biosciences & Diagnostic Solutions, and governance updates.

Summary

• Waters Corporation held its 2026 Annual Meeting of Shareholders virtually on May 21, 2026.
• The company reported strong financial results for the fiscal year ended December 31, 2025, with full-year sales growing 7% and adjusted earnings per share increasing 11% to $13.13.
• A significant strategic move was the acquisition of BD's Biosciences & Diagnostic Solutions businesses, which closed in February 2026, aimed at broadening capabilities and positioning Waters for long-term growth.
• The Board of Directors has been strengthened with expertise in genomics, infectious diseases, and molecular diagnostics following the acquisition.
• Key priorities for the Board in 2026 and beyond include overseeing the integration process, robust human capital management for an expanded workforce of approximately 16,000, and continued shareholder engagement.
• The company highlighted its commitment to strong corporate governance, including Board refreshment and majority voting for directors in uncontested elections.
• PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for fiscal year 2026.
• Shareholders were asked to vote on the compensation of executive officers on a non-binding advisory basis.
• The filing details executive compensation, including base salary, annual incentive awards, and long-term equity incentives, with a focus on performance-based compensation.
• The company's Total Shareholder Return (TSR) has outperformed peer averages over 1, 3, and 5-year periods, with a 5-year TSR of 54% as of December 31, 2025.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this filing positively due to strong financial performance, a strategic acquisition, and robust governance, indicating a company well-positioned for future growth.

Positives

• Delivered industry-leading financial results for fiscal year 2025, with 7% sales growth and 11% increase in adjusted EPS to $13.13.
• Successfully completed the transformative acquisition of BD's Biosciences & Diagnostic Solutions businesses, enhancing market position.
• Achieved a 54% 5-year Total Shareholder Return (TSR) as of December 31, 2025, outperforming peer averages.
• Strengthened the Board of Directors with new expertise aligned to the expanded business.
• Maintained strong corporate governance practices, including Board refreshment and majority voting for directors.
• Innovation remains a strong driver, with flagship platforms like Alliance iS HPLC more than doubling sales and Xevo TQ Absolute mass spectrometers and MaxPeak Premier chemistry delivering over 30% growth.
• The company's enterprise risk management framework and cybersecurity oversight are robust.
• Shareholder engagement is a priority, with feedback informing compensation program changes.
• 82% of shareholders voted in favor of the 2025 Say-on-Pay proposal, indicating confidence in executive compensation programs.

Negatives

• For the 2023 PSU awards, performance was below threshold on the adjusted non-GAAP OCCRG metric, though above the median of the S&P 500 Health Care Index on the relative total shareholder return metric.
• The CEO-to-median employee pay ratio was approximately 153-to-1 for fiscal year 2025, indicating a significant disparity.

Risks

• The company's actual future results may differ significantly from forward-looking statements due to various factors, as discussed in the Risk Factors section of its Annual Report on Form 10-K.
• Integration of the acquired BD businesses presents operational and strategic challenges.
• Potential risks associated with human capital management for an expanded global workforce of approximately 16,000.
• Regulatory considerations related to the integration process.
• The company's enterprise risk management framework is in place, but the effectiveness of risk mitigation is an ongoing concern.

Future Outlook

Looking ahead to 2026 and beyond, the Board's priorities include disciplined oversight of the integration process following the BD acquisition, robust human capital management for the expanded global workforce, and continued shareholder engagement. The company is confident in its ability to deliver sustained, industry-leading performance.

Management Comments

• "The past year has been a defining one for Waters. We delivered industry-leading financial results and took a significant step toward becoming a differentiated, global life sciences and diagnostics leader through the acquisition of BDs Biosciences & Diagnostic Solutions businesses."
• "Our focus is clear: to execute as a combined organization and deliver the full potential of the transaction."
• "Throughout 2025, Waters delivered strong financial results that led the industry, while advancing the transformative acquisition of BDs Biosciences and Diagnostic Solutions businesses, which closed earlier this year."
• "We executed with discipline, launched new pioneering innovation, and strengthened our foundation for sustained long-term growth."
• "At Waters, we accelerate the benefits of pioneering science. Every day, we work alongside customers to solve complex challenges..."
• "As we enter 2026, we are moving swiftly into executing our integration plan, applying the same operating discipline and playbook that has driven Waters success, while remaining focused on delivering attractive growth, margin expansion, and long-term shareholder returns."

Industry Context

StockSavvy.ai notes that Waters Corporation's strategic acquisition of BD's Biosciences & Diagnostic Solutions business positions it to compete more effectively in the growing life sciences and diagnostics market, a sector characterized by increasing demand for advanced analytical technologies and integrated solutions.

Comparison to Industry Standards

• Waters Corporation's 5-year TSR of 54% as of December 31, 2025, outperformed peer averages.
• For fiscal year 2025, the company delivered 2% TSR, outperforming the average of major Life Science Tools peers in a challenging macro environment.
• The company's peer group for executive compensation benchmarking includes companies like Agilent, Avantor, Bio-Rad, Bio-Techne, Charles River Laboratories, Cooper Companies, Edwards Lifesciences, Hologic, IDEXX Laboratories, Illumina, Mettler-Toledo, ResMed, Revvity, STERIS, Teleflex, and West Pharmaceutical.
• The SIC Code 3826 Index (Laboratory Analytical Instruments) showed a cumulative total return of 69% from December 31, 2020, to December 31, 2025, compared to Waters' 154% TSR over the same period.

Management Changes

Corporate Governance

Related Party Transactions

• Ordinary course business transactions conducted on an arms length basis with Galderma S.A. (of which Dr. Flemming Ornskov is CEO), Avient Corp. (of which Mr. Fearon is an independent director), Boston Scientific Corporation (of which Mr. Brennan served as CFO until June 2025), Solventum Corporation (of which Ms. Knight is Chief Commercial Officer), and Baxter International Inc. (of which Ms. Knight served as EVP until October 2025) are pre-approved or ratified under the Related Party Transactions Policy.

Stakeholder Impact

• Shareholders: The acquisition and financial performance are expected to drive long-term shareholder value. Shareholder feedback has influenced compensation program adjustments.
• Employees: The expanded organization will have approximately 16,000 global employees. Robust human capital management is a key priority.
• Customers: The combined entity aims to accelerate the benefits of pioneering science, helping customers advance life-saving therapies, ensure food and water safety, and improve patient outcomes.
• Management: Executive compensation is closely tied to company performance and shareholder value creation, with significant portions being at-risk.

Next Steps

• Elect directors to serve for the ensuing year.
• Ratify the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2026.
• Approve, on a non-binding, advisory basis, the compensation of the company's executive officers.
• Execute the integration plan for the acquired BD businesses.
• Continue to focus on delivering attractive growth, margin expansion, and long-term shareholder returns.

Key Dates

Recommendation

While the company reported strong financial results and a strategic acquisition, the proxy statement primarily focuses on governance and executive compensation. The integration of the acquired business and its long-term impact on financial performance require further monitoring. Therefore, a 'hold' recommendation is appropriate pending clearer visibility into the integration's success and its contribution to future growth.

Keywords

Waters Corporation, Proxy Statement, DEF 14A, Annual Meeting, Shareholder Meeting, Corporate Governance, Executive Compensation, Director Election, Acquisition, BD Biosciences, Life Sciences, Diagnostics, Financial Results, SEC Filing